Top Markets
#1 MarsCoin MarsCoin +44.69%
#2 Palladium Network Palladium Network +27.93%
#3 Siren Siren +26.64%
#4 Status Status +22.00%
#5 Useless Coin Useless Coin +18.14%
#6 BankrCoin BankrCoin +16.55%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
#8 Ankr Network Ankr Network +12.62%
#9 Hive Hive +11.82%
#10 Bedrock Bedrock +11.80%
Coin of the day
MarsCoin MarsCoin
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Classificação em ações #18278
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Preço da ação
$1.79
Última sincronização: 2026-09-02
Valor de mercado
$205.75M
Variação (1 dia)
3.18%
Variação (1 ano)
-61.61%
País
US
Negociar NovaBridge Biosciences (NBP)

Categoria

Healthcare
Receita da NovaBridge Biosciences (NBP)
Receita em Sep 2026 TTM: 0
De acordo com os últimos relatórios financeiros da NovaBridge Biosciences, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da NovaBridge Biosciences de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH